MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above

GSK submits landmark IMPACT data to support expanded label for Trelegy Ellipta

GlaxoSmithKline and Innoviva announced the submission of the landmark InforMing the PAthway of COPD Treatment (IMPACT) data to the European Medicines Agency to support an expanded label for Trelegy Ellipta in Europe.

Approval of the submission would mean FF/UMEC/VI could be used by physicians to treat a wider population of patients with the condition who are at risk of an exacerbation and require triple therapy.

Dave Allen, Head, Respiratory Therapy Area, R&D, GSK said: 'This filing is primarily based on the IMPACT study, which clarifies the type of patient most likely to benefit from once-daily single inhaler triple therapy, and adds to the evidence supporting the clinical profile of Trelegy Ellipta. The submission reflects our confidence in this medicine, which we believe has the potential to be an effective treatment option for appropriate patients with COPD who require triple therapy for symptom relief and exacerbation reduction.'

At 9:26am: (LON:GSK) GlaxoSmithKline PLC share price was -1.8p at 1289.2p

Story provided by